{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-026987","form_type":"8-K","ticker":"CMPS","cik":"0001816590","company_name":"COMPASS Pathways plc","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.392301+00:00","generated_at":"2026-06-12T09:12:15.709354+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"COMPASS Pathways H1 2023 net loss $52.5M; Phase 3 psilocybin trials on track","bullets":["Net loss for H1 2023: $52.5M ($1.19 loss per share) vs $42.2M ($1.00) in H1 2022.","Cash $148.2M; secured $50M term loan from Hercules Capital, $28.1M drawn.","COMP360 Phase 3 TRD trials on track; topline data expected summer 2024 (COMP 005) and mid-2025 (COMP 006).","AMA accepted CPT III code for in-person psychedelic therapy support, aligning with COMP360 requirements.","ATAI exercised demand registration rights for 7,935,663 shares; filing required within 45 days."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-026987","json":"https://secwatch.observer/filing/0001628280-23-026987.json","markdown":"https://secwatch.observer/filing/0001628280-23-026987.md","text":"https://secwatch.observer/filing/0001628280-23-026987.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1816590/000162828023026987/0001628280-23-026987-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1816590/000162828023026987/cmps-20230803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T09:12:15.709354+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"916f0a453dc870d70043750c9ab3c6f486e2a34c","claim":"COMPASS Pathways plc reported six months ended June 30, 2023 results: net income $52.5 million, or $1.19 loss per share, EPS $1.19 loss per share. Guidance reaffirmed.","evidence_excerpt":"Net loss for the six months ended 30 June 2023 was $52.5 million, or $1.19 loss per share (including non-cash share-based compensation expense of $8.6 million)","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1816590/000162828023026987/0001628280-23-026987-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"six months ended June 30, 2023"},{"label":"Net income","value":"$52.5 million, or $1.19 loss per share"},{"label":"EPS","value":"$1.19 loss per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"b52d128c94b6273f44b1ce8ec34d60cd5809edf4","claim":"COMPASS Pathways plc reported second quarter 2023 results: net income $28.3 million, or $0.62 loss per share, EPS $0.62 loss per share. Guidance reaffirmed.","evidence_excerpt":"Net loss for the three months ended 30 June 2023 was $28.3 million, or $0.62 loss per share (including non-cash share-based compensation expense of $4.6 million)","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1816590/000162828023026987/0001628280-23-026987-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter 2023"},{"label":"Net income","value":"$28.3 million, or $0.62 loss per share"},{"label":"EPS","value":"$0.62 loss per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}